LENZ Therapeutics (LENZ) Long-Term Investments (2022)
LENZ Therapeutics (LENZ) reported Long-Term Investments of $15.3 million for Q4 2022, up 14.32% on a QoQ basis from $13.4 million in Q3 2022.
LENZ Therapeutics (LENZ) has 1 years of Long-Term Investments data on file, last reported at $15.3 million in Q4 2022.
- Quarterly Long-Term Investments changed N/A year-over-year to $15.3 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $15.3 million (changed N/A YoY) and the FY2022 annual result came in at $15.3 million, changed N/A from the prior year.
- Long-Term Investments improved to $15.3 million in Q4 2022 per LENZ's latest filing, from $13.4 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $15.3 million in Q4 2022 and bottomed at $6.0 million in Q2 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 505,194.89 |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 9.79 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 22.17 Mn |
| 10 | LENZ Therapeutics | 235.77 Mn | 235.77 Mn | 825,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 15.32 Mn |
| Sep 30, 2022 | 13.40 Mn |
| Jun 30, 2022 | 5.99 Mn |
| Mar 31, 2022 | 12.93 Mn |